Plain English summary of "Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Heptocellular Carcinoma"
Published Ocober 2016 in Journal of Gastrointestinal Surgery Link to full PDF, courtesy Springer
Cancer staging describes the severity of an individual's cancer based on the magnitude of the primary tumor as well as on the extent cancer has spread in the body. Understanding the stage of the cancer helps doctors determine the prognosis and design a treatment plan for individual patients. Fibrolamellar carcinoma (FLC) is staged according to the American Joint Committee on Cancer (AJCC) staging for Hepatocellular carcinoma (HCC). AJCC stage IV is defined by the presence of lymph node or distant metastasis. Researchers from MD Anderson examined the records of 65 FLC patients who underwent curative resection of their tumor, between 1990 and 2015, and compared them to 158 patients with HCC arising in livers that did not contain significant scarring (i.e. cirrhosis). HCC without cirrhosis was chosen for comparison to isolate the effect of the cancer on survival from that of an underlying liver disease. They found that 46% of patients with FLC had stage IV disease, compared with only 6% of those with HCC. In patients with stage IV FLC, 81% had isolated metastasis to lymph nodes. The presence of lymph node metastases in FLC did not effect their overall survival (OS) and recurrence free survival (RFS). OS in FLC was affected by the number of tumors, and both OS and RFS were affected by the presence of vascular invasion.
--- Dr. Gadi Lalazar, Fibrolamellar Registry Scientific Advisory Board